메뉴 건너뛰기




Volumn 1499, Issue , 2017, Pages 1-11

Introduction to RNA vaccines

Author keywords

Messenger RNA; Replicon; RNA vaccine; RNA virus vector; Self amplifying RNA

Indexed keywords

IMMUNOLOGICAL ADJUVANT; MESSENGER RNA; RNA VACCINE; RNA; VACCINE;

EID: 85007168435     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-6481-9_1     Document Type: Chapter
Times cited : (40)

References (69)
  • 2
    • 0032077973 scopus 로고    scopus 로고
    • A simplified vaccinologists’ vaccinology and the pursuit of a vaccine against AIDS
    • Hilleman MR (1998) A simplified vaccinologists’ vaccinology and the pursuit of a vaccine against AIDS. Vaccine 16(8):778–793
    • (1998) Vaccine , vol.16 , Issue.8 , pp. 778-793
    • Hilleman, M.R.1
  • 3
    • 84929251318 scopus 로고    scopus 로고
    • Vaccinology in the era of high-throughput biology
    • Nakaya HI, Pulendran B (2015) Vaccinology in the era of high-throughput biology. Phil Trans R Soc Lond B Biol Sci 370. pii: 20140146. doi:10.1098/rstb.2014.0146
    • (2015) Phil Trans R Soc Lond B Biol Sci , vol.370
    • Nakaya, H.I.1    Pulendran, B.2
  • 4
    • 84954553168 scopus 로고    scopus 로고
    • Broadly neutralizing antibodies against HIV: New insights to inform vaccine design
    • Sadanand S, Suscovich TJ, Alter G (2016) Broadly neutralizing antibodies against HIV: new insights to inform vaccine design. Annu Rev Med 67:185–200. doi:10.1146/annurev-med-091014-090749
    • (2016) Annu Rev Med , vol.67 , pp. 185-200
    • Sadanand, S.1    Suscovich, T.J.2    Alter, G.3
  • 5
    • 84938603864 scopus 로고    scopus 로고
    • Hepatitis C virus: Why do we need a vaccine to prevent a curable persistent infection?
    • Walker CM, Grakoui A (2015) Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection? Curr Opin Immunol 35:137–143. doi:10.1016/j.coi.2015.06.010
    • (2015) Curr Opin Immunol , vol.35 , pp. 137-143
    • Walker, C.M.1    Grakoui, A.2
  • 6
    • 84960372950 scopus 로고    scopus 로고
    • Vaccines for established cancer: Overcoming the challenges posed by immune evasion
    • van der Burg SH, Arens R, Ossendorp F et al (2016) Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16:219–233. doi:10.1038/nrc.2016.16
    • (2016) Nat Rev Cancer , vol.16 , pp. 219-233
    • Van Der Burg, S.H.1    Arens, R.2    Ossendorp, F.3
  • 7
    • 84963631903 scopus 로고    scopus 로고
    • Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures
    • Nakaya HI, Hagan T, Duraisingham SS et al (2015) Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures. Immunity 43:1186–1198. doi:10.1016/j.immuni.2015.11.012
    • (2015) Immunity , vol.43 , pp. 1186-1198
    • Nakaya, H.I.1    Hagan, T.2    Duraisingham, S.S.3
  • 8
    • 84929598198 scopus 로고    scopus 로고
    • Decoding viral infection by ribosome profiling
    • Stern-Ginossar N (2015) Decoding viral infection by ribosome profiling. J Virol 89:6164–6166. doi:10.1128/JVI.02528-14
    • (2015) J Virol , vol.89 , pp. 6164-6166
    • Stern-Ginossar, N.1
  • 9
    • 84928770388 scopus 로고    scopus 로고
    • Neoantigens in cancer immunotherapy
    • Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69–74. doi:10.1126/science.aaa4971
    • (2015) Science , vol.348 , pp. 69-74
    • Schumacher, T.N.1    Schreiber, R.D.2
  • 10
    • 33750862932 scopus 로고    scopus 로고
    • Vaccine manufacturing: Challenges and solutions
    • Ulmer JB, Valley U, Rappuoli R (2006) Vaccine manufacturing: challenges and solutions. Nat Biotechnol 24(11):1377–1383
    • (2006) Nat Biotechnol , vol.24 , Issue.11 , pp. 1377-1383
    • Ulmer, J.B.1    Valley, U.2    Rappuoli, R.3
  • 11
    • 84855810504 scopus 로고    scopus 로고
    • Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries
    • Hondowicz BD, Schwedhelm KV, Kas A et al (2012) Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries. PLoS One 7(1):e29949
    • (2012) Plos One , vol.7 , Issue.1
    • Hondowicz, B.D.1    Schwedhelm, K.V.2    Kas, A.3
  • 12
    • 3442896311 scopus 로고    scopus 로고
    • Messenger RNA-based vaccines
    • Pascolo S (2004) Messenger RNA-based vaccines. Expert Opin Biol Ther 4:1285–1294
    • (2004) Expert Opin Biol Ther , vol.4 , pp. 1285-1294
    • Pascolo, S.1
  • 13
    • 84921384147 scopus 로고    scopus 로고
    • The messenger’s great message for vaccination
    • Pascolo S (2015) The messenger’s great message for vaccination. Expert Rev Vaccines 14:153–156. doi:10.1586/14760584.2015.1000871
    • (2015) Expert Rev Vaccines , vol.14 , pp. 153-156
    • Pascolo, S.1
  • 14
    • 84921794613 scopus 로고    scopus 로고
    • MRNA-based therapeutics--developing a new class of drugs
    • Sahin U, Karikó K, Türeci Ö (2014) mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov 13:759–780. doi:10.1038/nrd4278
    • (2014) Nat Rev Drug Discov , vol.13 , pp. 759-780
    • Sahin, U.1    Karikó, K.2    Türeci, Ö.3
  • 15
    • 84921508727 scopus 로고    scopus 로고
    • Vaccines “on demand”: Science fiction or a future reality
    • Ulmer JB, Mansoura MK, Geall AJ (2015) Vaccines “on demand”: science fiction or a future reality. Expert Opin Drug Discov 10:101–106. doi:10.1517/17460441.2015.996128
    • (2015) Expert Opin Drug Discov , vol.10 , pp. 101-106
    • Ulmer, J.B.1    Mansoura, M.K.2    Geall, A.J.3
  • 16
    • 84885730496 scopus 로고    scopus 로고
    • Messenger RNA-based vaccines: Progress, challenges, applications
    • Kramps T, Probst J (2013) Messenger RNA-based vaccines: progress, challenges, applications. Wiley Interdiscip Rev RNA 4:737–749. doi:10.1002/wrna.1189
    • (2013) Wiley Interdiscip Rev RNA , vol.4 , pp. 737-749
    • Kramps, T.1    Probst, J.2
  • 17
    • 84938827008 scopus 로고    scopus 로고
    • Modified mRNA as an alternative to plasmid DNA (PDNA) for transcript replacement and vaccination therapy
    • Youn H, Chung J-K (2015) Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy. Expert Opin Biol Ther 15:1337–1348. doi:10.1517/14712598.2015.1057563
    • (2015) Expert Opin Biol Ther , vol.15 , pp. 1337-1348
    • Youn, H.1    Chung, J.-K.2
  • 18
    • 0025231388 scopus 로고
    • Direct gene transfer into mouse muscle in vivo
    • Wolff JA, Malone RW, Williams P et al (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468
    • (1990) Science , vol.247 , pp. 1465-1468
    • Wolff, J.A.1    Malone, R.W.2    Williams, P.3
  • 19
    • 0032747388 scopus 로고    scopus 로고
    • DNA and RNA-based vaccines: Principles, progress and prospects
    • Leitner WW, Ying H, Restifo NP (1999) DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18:765–777. doi:10.1016/S0264-410X(99)00271-6
    • (1999) Vaccine , vol.18 , pp. 765-777
    • Leitner, W.W.1    Ying, H.2    Restifo, N.P.3
  • 20
    • 44949195901 scopus 로고    scopus 로고
    • Results of the first phase I/II clinical vaccination trial with direct injection of mRNA
    • Weide B, Carralot J-P, Reese A et al (2008) Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 31(2):180–188
    • (2008) J Immunother , vol.31 , Issue.2 , pp. 180-188
    • Weide, B.1    Carralot, J.-P.2    Reese, A.3
  • 21
    • 79955630363 scopus 로고    scopus 로고
    • Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients
    • Rittig SM, Haentschel M, Weimer KJ et al (2011) Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19(5):990–999
    • (2011) Mol Ther , vol.19 , Issue.5 , pp. 990-999
    • Rittig, S.M.1    Haentschel, M.2    Weimer, K.J.3
  • 22
    • 84939463741 scopus 로고    scopus 로고
    • Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond: Recombinant mRNA technology and its application
    • Vallazza B, Petri S, Poleganov MA et al (2015) Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond: Recombinant mRNA technology and its application. Wiley Interdiscip Rev RNA. doi:10.1002/wrna.1288
    • (2015) Wiley Interdiscip Rev RNA
    • Vallazza, B.1    Petri, S.2    Poleganov, M.A.3
  • 23
    • 84874724470 scopus 로고    scopus 로고
    • MRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
    • Van Lint S, Heirman C, Thielemans K, Breckpot K (2013) mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother 9(2):265–274
    • (2013) Hum Vaccin Immunother , vol.9 , Issue.2 , pp. 265-274
    • Van Lint, S.1    Heirman, C.2    Thielemans, K.3    Breckpot, K.4
  • 24
    • 0033999511 scopus 로고    scopus 로고
    • Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA
    • Granstein RD, Ding W, Ozawa H (2000) Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol 114(4):632–636
    • (2000) J Invest Dermatol , vol.114 , Issue.4 , pp. 632-636
    • Granstein, R.D.1    Ding, W.2    Ozawa, H.3
  • 25
    • 0029839058 scopus 로고    scopus 로고
    • Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
    • Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184(2):465–472
    • (1996) J Exp Med , vol.184 , Issue.2 , pp. 465-472
    • Boczkowski, D.1    Nair, S.K.2    Snyder, D.3    Gilboa, E.4
  • 26
    • 77949440365 scopus 로고    scopus 로고
    • RNA as performance-enhancers for dendritic cells
    • Boczkowski D, Nair S (2010) RNA as performance-enhancers for dendritic cells. Expert Opin Biol Ther 10:563–574. doi:10.1517/14712591003614749
    • (2010) Expert Opin Biol Ther , vol.10 , pp. 563-574
    • Boczkowski, D.1    Nair, S.2
  • 27
    • 84870869040 scopus 로고    scopus 로고
    • Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
    • Petsch B, Schnee M, Vogel AB et al (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30(12):1210–1216
    • (2012) Nat Biotechnol , vol.30 , Issue.12 , pp. 1210-1216
    • Petsch, B.1    Schnee, M.2    Vogel, A.B.3
  • 28
    • 84865994357 scopus 로고    scopus 로고
    • Nonviral delivery of self-amplifying RNA vaccines
    • Geall AJ, Verma A, Otten GR et al (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 109(36): 14604–14609
    • (2012) Proc Natl Acad Sci U S A , vol.109 , Issue.36 , pp. 14604-14609
    • Geall, A.J.1    Verma, A.2    Otten, G.R.3
  • 29
    • 84927176976 scopus 로고    scopus 로고
    • A cationic nanoemulsion for the delivery of next-generation RNA vaccines
    • Brito LA, Chan M, Shaw CA et al (2014) A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther. doi:10.1038/mt.2014.133
    • (2014) Mol Ther
    • Brito, L.A.1    Chan, M.2    Shaw, C.A.3
  • 30
    • 84930673065 scopus 로고    scopus 로고
    • Business: The billion-dollar biotech
    • Dolgin E (2015) Business: The billion-dollar biotech. Nature 522:26–28. doi:10.1038/522026a
    • (2015) Nature , vol.522 , pp. 26-28
    • Dolgin, E.1
  • 32
    • 85007210773 scopus 로고    scopus 로고
    • Vol. 29, No. 2, 2015 - Proposed International Nonproprietary Names, List 113, Accessed 29 Mar 2016
    • WHO Drug Information Vol. 29, No. 2, 2015 - Proposed International Nonproprietary Names, List 113. http://apps.who.int/medicinedocs/en/m/abstract/Js22000en/. Accessed 29 Mar 2016
  • 33
    • 34548431318 scopus 로고    scopus 로고
    • Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: Implication for therapeutic RNA development
    • Karikó K, Weissman D (2007) Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr Opin Drug Discov Devel 10(5):523–532
    • (2007) Curr Opin Drug Discov Devel , vol.10 , Issue.5 , pp. 523-532
    • Karikó, K.1    Weissman, D.2
  • 37
    • 84863549346 scopus 로고    scopus 로고
    • Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity
    • Uematsu Y, Vajdy M, Lian Y et al (2012) Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity. Clin Vaccine Immunol 19:991–998. doi:10.1128/CVI.00031-12
    • (2012) Clin Vaccine Immunol , vol.19 , pp. 991-998
    • Uematsu, Y.1    Vajdy, M.2    Lian, Y.3
  • 38
    • 85007249243 scopus 로고    scopus 로고
    • Humana Press, Totowa, NJ
    • Nielsen H (2011) RNA. Humana Press, Totowa, NJ
    • (2011) RNA
    • Nielsen, H.1
  • 39
    • 84908671756 scopus 로고    scopus 로고
    • Translation of genomics-guided RNAbased personalised cancer vaccines: Towards the bedside
    • Boisguérin V, Castle JC, Loewer M et al (2014) Translation of genomics-guided RNAbased personalised cancer vaccines: towards the bedside. Br J Cancer 111:1469–1475. doi:10.1038/bjc.2013.820
    • (2014) Br J Cancer , vol.111 , pp. 1469-1475
    • Boisguérin, V.1    Castle, J.C.2    Loewer, M.3
  • 40
    • 84862855875 scopus 로고    scopus 로고
    • Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination
    • Desmet CJ, Ishii KJ (2012) Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 12(7):479–491
    • (2012) Nat Rev Immunol , vol.12 , Issue.7 , pp. 479-491
    • Desmet, C.J.1    Ishii, K.J.2
  • 41
    • 21044440406 scopus 로고    scopus 로고
    • Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA
    • Scheel B, Teufel R, Probst J et al (2005) Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35:1557– 1566. doi:10.1002/eji.200425656
    • (2005) Eur J Immunol 35:1557– , pp. 1566
    • Scheel, B.1    Teufel, R.2    Probst, J.3
  • 42
    • 77953931139 scopus 로고    scopus 로고
    • Particle size and activation threshold: A new dimension of danger signaling
    • Rettig L, Haen SP, Bittermann AG et al (2010) Particle size and activation threshold: a new dimension of danger signaling. Blood 115(22):4533–4541
    • (2010) Blood , vol.115 , Issue.22 , pp. 4533-4541
    • Rettig, L.1    Haen, S.P.2    Bittermann, A.G.3
  • 43
    • 78650640612 scopus 로고    scopus 로고
    • Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity
    • Fotin-Mleczek M, Duchardt KM, Lorenz C et al (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34(1):1–15
    • (2011) J Immunother , vol.34 , Issue.1 , pp. 1-15
    • Fotin-Mleczek, M.1    Duchardt, K.M.2    Lorenz, C.3
  • 45
    • 84896958063 scopus 로고    scopus 로고
    • Innate immune sensing and signaling of cytosolic nucleic acids
    • Wu J, Chen ZJ (2014) Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol 32:461–488. doi:10.1146/annurev-immunol-032713-120156
    • (2014) Annu Rev Immunol , vol.32 , pp. 461-488
    • Wu, J.1    Chen, Z.J.2
  • 46
    • 84924794747 scopus 로고    scopus 로고
    • Emerging principles governing signal transduction by pattern-recognition receptors
    • Kagan JC, Barton GM (2015) Emerging principles governing signal transduction by pattern-recognition receptors. Cold Spring Harb Perspect Biol 7:a016253. doi:10.1101/cshperspect.a016253
    • (2015) Cold Spring Harb Perspect Biol , vol.7
    • Kagan, J.C.1    Barton, G.M.2
  • 47
    • 84889654582 scopus 로고    scopus 로고
    • Nucleic acids and endosomal pattern recognition: How to tell friend from foe?
    • Brencicova E, Diebold SS (2013) Nucleic acids and endosomal pattern recognition: how to tell friend from foe? Front Cell Infect Microbiol 3:37. doi:10.3389/fcimb.2013.00037
    • (2013) Front Cell Infect Microbiol , vol.3 , pp. 37
    • Brencicova, E.1    Diebold, S.S.2
  • 48
    • 48549097394 scopus 로고    scopus 로고
    • Accessing the therapeutic potential of immunostimulatory nucleic acids
    • Barchet W, Wimmenauer V, Schlee M, Hartmann G (2008) Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol 20(4):389–395
    • (2008) Curr Opin Immunol , vol.20 , Issue.4 , pp. 389-395
    • Barchet, W.1    Wimmenauer, V.2    Schlee, M.3    Hartmann, G.4
  • 49
    • 84859417996 scopus 로고    scopus 로고
    • Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy
    • Van Lint S, Goyvaerts C, Maenhout S et al (2012) Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 72(7):1661–1671
    • (2012) Cancer Res , vol.72 , Issue.7 , pp. 1661-1671
    • Van Lint, S.1    Goyvaerts, C.2    Maenhout, S.3
  • 50
    • 84951802073 scopus 로고    scopus 로고
    • In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf
    • Hammerich L, Binder A, Brody JD (2015) In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Mol Oncol 9:1966–1981. doi:10.1016/j. molonc.2015.10.016
    • (2015) Mol Oncol , vol.9 , pp. 1966-1981
    • Hammerich, L.1    Binder, A.2    Brody, J.D.3
  • 51
    • 84901502933 scopus 로고    scopus 로고
    • Chapter two - therapeutic cancer vaccines
    • Tew KD, Fisher PB (eds), Academic, New York
    • Schlom J, Hodge JW, Palena C et al (2014) Chapter two - therapeutic cancer vaccines. In: Tew KD, Fisher PB (eds) Advances in cancer research. Academic, New York, pp 67–124
    • (2014) Advances in Cancer Research , pp. 67-124
    • Schlom, J.1    Hodge, J.W.2    Palena, C.3
  • 52
    • 84921411206 scopus 로고    scopus 로고
    • RNA-based viral vectors
    • Mogler MA, Kamrud KI (2015) RNA-based viral vectors. Expert Rev Vaccines 14:283–312. doi:10.1586/14760584.2015.979798
    • (2015) Expert Rev Vaccines , vol.14 , pp. 283-312
    • Mogler, M.A.1    Kamrud, K.I.2
  • 53
    • 84904644314 scopus 로고    scopus 로고
    • Oncolytic viruses and their application to cancer immunotherapy
    • Chiocca EA, Rabkin SD (2014) Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2:295–300. doi:10.1158/2326-6066.CIR-14-0015
    • (2014) Cancer Immunol Res , vol.2 , pp. 295-300
    • Chiocca, E.A.1    Rabkin, S.D.2
  • 54
    • 78049288264 scopus 로고    scopus 로고
    • Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns
    • Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10(11):787–796
    • (2010) Nat Rev Immunol , vol.10 , Issue.11 , pp. 787-796
    • Bachmann, M.F.1    Jennings, G.T.2
  • 55
    • 84903649476 scopus 로고    scopus 로고
    • Messenger RNA (MRNA) nanoparticle tumour vaccination
    • Phua KKL, Nair SK, Leong KW (2014) Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale 6:7715–7729. doi:10.1039/c4nr01346h
    • (2014) Nanoscale , vol.6 , pp. 7715-7729
    • Phua, K.1    Nair, S.K.2    Leong, K.W.3
  • 56
    • 78549283854 scopus 로고    scopus 로고
    • Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity
    • Kreiter S, Selmi A, Diken M et al (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70(22):9031–9040
    • (2010) Cancer Res , vol.70 , Issue.22 , pp. 9031-9040
    • Kreiter, S.1    Selmi, A.2    Diken, M.3
  • 57
    • 84968795505 scopus 로고    scopus 로고
    • Needle free injection technology: A complete insight
    • Ravi AD, Sadhna D, Nagpaal D, Chawla L (2015) Needle free injection technology: a complete insight. Int J Pharm Investig 5:192–199. doi:10.4103/2230-973X.167662
    • (2015) Int J Pharm Investig , vol.5 , pp. 192-199
    • Ravi, A.D.1    Sadhna, D.2    Nagpaal, D.3    Chawla, L.4
  • 58
    • 84974712289 scopus 로고    scopus 로고
    • Thermostable subunit vaccines for pulmonary delivery: How close are we?
    • Foged C (2016) Thermostable subunit vaccines for pulmonary delivery: how close are we? Curr Pharm Des 22(17):2561–2576
    • (2016) Curr Pharm Des , vol.22 , Issue.17 , pp. 2561-2576
    • Foged, C.1
  • 59
    • 84861186775 scopus 로고    scopus 로고
    • HIV-1 mRNA electroporation of PBMC: A simple and efficient method to monitor T-cell responses against autologous HIV-1 in HIV-1-infected patients
    • Etschel JK, Hückelhoven AG, Hofmann C et al (2012) HIV-1 mRNA electroporation of PBMC: a simple and efficient method to monitor T-cell responses against autologous HIV-1 in HIV-1-infected patients. J Immunol Methods 380:40–55. doi:10.1016/j.jim.2012.03.005
    • (2012) J Immunol Methods , vol.380 , pp. 40-55
    • Etschel, J.K.1    Hückelhoven, A.G.2    Hofmann, C.3
  • 60
    • 77949918477 scopus 로고    scopus 로고
    • Efficient mRNA electroporation of peripheral blood mononuclear cells to detect memory T cell responses for immunomonitoring purposes
    • Van Camp K, Cools N, Stein B et al (2010) Efficient mRNA electroporation of peripheral blood mononuclear cells to detect memory T cell responses for immunomonitoring purposes. J Immunol Methods 354:1–10. doi:10.1016/j.jim.2010.01.009
    • (2010) J Immunol Methods , vol.354 , pp. 1-10
    • Van Camp, K.1    Cools, N.2    Stein, B.3
  • 61
    • 84878641684 scopus 로고    scopus 로고
    • Berneman Z (2013) mRNA electroporation as a tool for immunomonitoring
    • Cools N, Van Camp K, Van Tendeloo V, Berneman Z (2013) mRNA electroporation as a tool for immunomonitoring. Methods Mol Biol 969:293–303
    • Methods Mol Biol , vol.969 , pp. 293-303
    • Cools, N.1    Van Camp, K.2    Van Tendeloo, V.3
  • 62
    • 84940970806 scopus 로고    scopus 로고
    • Anti-infective vaccination in the 21st century — new horizons for personal and public health
    • Scully IL, Swanson K, Green L et al (2015) Anti-infective vaccination in the 21st century — new horizons for personal and public health. Curr Opin Microbiol 27:96–102. doi:10.1016/j.mib.2015.07.006
    • (2015) Curr Opin Microbiol , vol.27 , pp. 96-102
    • Scully, I.L.1    Swanson, K.2    Green, L.3
  • 63
    • 84924931797 scopus 로고    scopus 로고
    • The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines
    • Lopalco PL, DeStefano F (2015) The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Vaccine 33:1541–1548. doi:10.1016/j.vaccine.2014.10.047
    • (2015) Vaccine , vol.33 , pp. 1541-1548
    • Lopalco, P.L.1    Destefano, F.2
  • 64
    • 77956656512 scopus 로고    scopus 로고
    • First-in-human clinical trials with vaccines— what regulators want
    • Goetz KB, Pfleiderer M, Schneider CK (2010) First-in-human clinical trials with vaccines— what regulators want. Nat Biotechnol 28:910–916. doi:10.1038/nbt0910-910
    • (2010) Nat Biotechnol , vol.28 , pp. 910-916
    • Goetz, K.B.1    Pfleiderer, M.2    Schneider, C.K.3
  • 66
    • 84855383397 scopus 로고    scopus 로고
    • Intradermal electroporation of naked replicon RNA elicits strong immune responses
    • Johansson DX, Ljungberg K, Kakoulidou M, Liljeström P (2012) Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One 7:e29732. doi:10.1371/journal.pone.0029732
    • (2012) Plos One , pp. 7
    • Johansson, D.X.1    Ljungberg, K.2    Kakoulidou, M.3    Liljeström, P.4
  • 67
    • 84901269661 scopus 로고    scopus 로고
    • Enhanced delivery and potency of self-amplifying mRNA vaccines by electroporation in situ
    • Cu Y, Broderick KE, Banerjee K et al (2013) Enhanced delivery and potency of self-amplifying mRNA vaccines by electroporation in situ. Vaccines 1:367–383. doi:10.3390/vaccines1030367
    • (2013) Vaccines , vol.1 , pp. 367-383
    • Cu, Y.1    Broderick, K.E.2    Banerjee, K.3
  • 68
    • 84921405665 scopus 로고    scopus 로고
    • Electroporation-enhanced delivery of nucleic acid vaccines
    • Broderick KE, Humeau LM (2015) Electroporation-enhanced delivery of nucleic acid vaccines. Expert Rev Vaccines 14(2):195–204. doi:10.1586/14760584.2015.990890
    • (2015) Expert Rev Vaccines , vol.14 , Issue.2 , pp. 195-204
    • Broderick, K.E.1    Humeau, L.M.2
  • 69
    • 84885659334 scopus 로고    scopus 로고
    • The regulatory landscape for actively personalized cancer immunotherapies
    • Britten CM, Singh-Jasuja H, Flamion B et al (2013) The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol 31:880–882. doi: 10.1038/nbt.2708
    • (2013) Nat Biotechnol , vol.31 , pp. 880-882
    • Britten, C.M.1    Singh-Jasuja, H.2    Flamion, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.